


10/711513

Structure
Search

=> d que stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L2 8 SEA FILE=REGISTRY SSS FUL L1

L3 8 SEA L2

L4 8 DUP REM L3 (0 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 17:35:40 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 17:35:54 ON 26 JAN 2006

L1 STRUCTURE UPLOADED

L2 8 S L1 FULL

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:36:52 ON 26 JAN 2006

L3 8 S L2

L4 8 DUP REM L3 (0 DUPLICATES REMOVED)

=>

10/311513

Reg # Search

=> d his

(FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006

L1 1 S 283173-50-2/RN

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006

L2 8 S L1

L3 7 S L2 AND CANCER

L4 1 S L3 AND IRENOTECAN

L5 1 S L3 AND TEMOZOLAMIDE

L6 2 S L3 AND DACARBAZINE

L7 7 DUP REM L3 (0 DUPLICATES REMOVED)

L8 7 S L3-L6

L9 7 DUP REM L8 (0 DUPLICATES REMOVED)

10/811513

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAAAL1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9
DICTIONARY FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s 283173-50-2/rn
L1      1 283173-50-2/RN
```

```
=> d L1
```

```
L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN  283173-50-2  REGISTRY
ED  Entered STN:  04 Aug 2000
CN  6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-
    [(methylamino)methyl]phenyl]- (9CI)  (CA INDEX NAME)
FS  3D CONCORD
MF  C19 H18 F N3 O
CI  COM
SR  CA
LC  STN Files:  CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, TOXCENTER, USPAT2,
    USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus uspatful pubmed
'PUBMED' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.34	2.55

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 17:45:32 ON 26 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s L1

L2 8 L1

=> s L2 and cancer

L3 7 L2 AND CANCER

=> s L3 and irenotecan

L4 1 L3 AND IRENOTECAN

=> s L3 and temozolamide

L5 1 L3 AND TEMOZOLAMIDE

=> s L3 and dacarbazine

L6 2 L3 AND DACARBAZINE

=> d L6 1-2 ibib abs hitstr

L6 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857605 HCAPLUS


DOCUMENT NUMBER: 141:325793

TITLE: Poly(ADP-ribose) polymerase (PARP) inhibitor

8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-tetrahydroazepino[5,4,3-cd]indol-6-one salts for therapeutic use

INVENTOR(S): Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia; Matthews, Jean Joo
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329
PRIORITY APPLN. INFO.:			US 2003-459433P	P 20030331
			WO 2004-IB915	W 20040319
AB	Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.			
IT	283173-50-2 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses) (PARP inhibitor tetrahydroazepinoindolone derivative salts for therapeutic use)			
RN	283173-50-2 HCAPLUS			
CN	6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)			



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:315203 USPATFULL

TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases

INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
 Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
 Liu, Jia, La Jolla, CA, UNITED STATES
 Matthews, Jean, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248879	A1	20041209
APPLICATION INFO.:	US 2004-811513	A1	20040329 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459433P	20030331 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 283173-50-2

(PARP inhibitor tetrahydroazepinoindolone derivative salts for therapeutic use)

RN 283173-50-2 USPATFULL

CN 6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006

L1 1 S 283173-50-2/RN

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006

L2 8 S L1
 L3 7 S L2 AND CANCER
 L4 1 S L3 AND IRENOTECAN
 L5 1 S L3 AND TEMOZOLAMIDE
 L6 2 S L3 AND DACARBAZINE

=> L3 dup rem

L3 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> dup rem L3

PROCESSING COMPLETED FOR L3

L7 7 DUP REM L3 (0 DUPLICATES REMOVED)

=> d L3 1-7 ibib abs

L3 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:120932 HCAPLUS

DOCUMENT NUMBER: 142:212321

TITLE: Tricyclic lactam indole derivatives and tricyclic
 lactam benzimidazole derivatives used in inhibiting
 PARP enzyme as therapeutic compounds

INVENTOR(S): Helleday, Thomas; Curtin, Nicola

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012305	A2	20050210	WO 2004-GB3183	20040723
WO 2005012305	A3	20050407		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005143370 A1 20050630 US 2004-898653 20040723
 PRIORITY APPLN. INFO.: GB 2003-17466 A 20030725
 GB 2004-8524 A 20040416

AB The invention relates to tricyclic lactam indole derivs. and tricyclic lactam benzimidazole derivs. and their use in inhibiting the activity of PARP enzyme (poly(ADP-ribose)polymerase). The invention also relates to the use of these compds. in the preparation of medicaments for treatment of cancer.

L3 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857605 HCAPLUS

DOCUMENT NUMBER: 141:325793

TITLE: Poly(ADP-ribose) polymerase (PARP) inhibitor
 8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-tetrahydroazepino[5,4,3-cd]indol-6-one salts for therapeutic use

INVENTOR(S): Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia; Matthews, Jean Joo

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329

PRIORITY APPLN. INFO.: US 2003-459433P P 20030331
 WO 2004-IB915 W 20040319

AB Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative

disease. As **cancer** therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:165945 USPATFULL
TITLE: Therapeutic compounds
INVENTOR(S): Helleday, Thomas, Stockholm, SWEDEN
Curtin, Nicola, Tyne and Wear, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143370	A1	20050630
APPLICATION INFO.:	US 2004-898653	A1	20040723 (10)

App SN 10/298653

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-17466	20030725
	GB 2004-8524	20040416

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOTARO AND MICHALOS, 100 DUTCH HILL ROAD, SUITE 110, ORANGEBURG, NY, 10962-2100, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1303

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to tricyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

✓ L3 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:99541 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES
PATENT ASSIGNEE(S): AGOURON PHARMACEUTICALS, INC. (U.S. corporation)
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085460	A1	20050421
	US 6977298	B2	20051220
APPLICATION INFO.:	US 2004-4261	A1	20041203 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-264018, filed on 2 Oct 2002, ABANDONED Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES
ROAD, LA JOLLA, CA, 92037, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 2893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1## As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:315203 USPATFULL
TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
Liu, Jia, La Jolla, CA, UNITED STATES
Matthews, Jean, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248879	A1	20041209
APPLICATION INFO.:	US 2004-811513	A1	20040329 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459433P	20030331 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:113513 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078254	A1	20030424

APPLICATION INFO.: US 2002-264018 A1 20021002 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-479896, filed on 10
Jan 2000, GRANTED, Pat. No. US 6495541

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Agouron Pharmaceuticals, Inc., 10777 Science Center Road, San Diego, CA, 92121	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3013	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1##

As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:332731 USPATFULL

TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases

INVENTOR(S): Webber, Stephen Evan, San Diego, CA, United States
Canan-Koch, Stacie S., La Jolla, CA, United States
Tikhe, Jayashree, San Diego, CA, United States
Thoresen, Lars Henrik, College Station, TX, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495541	B1	20021217
APPLICATION INFO.:	US 2000-479896		20000110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Shanks & Herbert	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3029	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1##

As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s L3-L6

L8 7 (L3 OR L4 OR L5 OR L6)

=> dup rem

ENTER L# LIST OR (END):L8

PROCESSING COMPLETED FOR L8

L9 7 DUP REM L8 (0 DUPLICATES REMOVED)

=> d L8 ibib abs

L8 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:120932 HCAPLUS

DOCUMENT NUMBER: 142:212321

TITLE: Tricyclic lactam indole derivatives and tricyclic
lactam benzimidazole derivatives used in inhibiting
PARP enzyme as therapeutic compounds

INVENTOR(S): Helleday, Thomas; Curtin, Nicola

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012305	A2	20050210	WO 2004-GB3183	20040723
WO 2005012305	A3	20050407		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005143370	A1	20050630	US 2004-898653	20040723
PRIORITY APPLN. INFO.:			GB 2003-17466	A 20030725
			GB 2004-8524	A 20040416

AB The invention relates to tricyclic lactam indole derivs. and tricyclic lactam benzimidazole derivs. and their use in inhibiting the activity of PARP enzyme (poly(ADP-ribose)polymerase). The invention also relates to the use of these compds. in the preparation of medicaments for treatment of cancer.

=> d L8 ibib abs 2-7

L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857605 HCAPLUS

DOCUMENT NUMBER: 141:325793

TITLE: Poly(ADP-ribose) polymerase (PARP) inhibitor
8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-tetrahydroazepino[5,4,3-cd]indol-6-one salts for therapeutic use

INVENTOR(S): Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia; Matthews, Jean Joo

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329
PRIORITY APPLN. INFO.:			US 2003-459433P	P 20030331
			WO 2004-IB915	W 20040319
AB Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.				
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L8 ANSWER 3 OF 7 USPATFULL on STN
 ACCESSION NUMBER: 2005:165945 USPATFULL
 TITLE: Therapeutic compounds
 INVENTOR(S): Helleday, Thomas, Stockholm, SWEDEN
 Curtin, Nicola, Tyne and Wear, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143370	A1	20050630
APPLICATION INFO.:	US 2004-898653	A1	20040723 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-17466	20030725
	GB 2004-8524	20040416
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NOTARO AND MICHALOS, 100 DUTCH HILL ROAD, SUITE 110, ORANGEBURG, NY, 10962-2100, US	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1303	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention relates to tricyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:99541 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES
PATENT ASSIGNEE(S): AGOURON PHARMACEUTICALS, INC. (U.S. corporation)
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085460	A1	20050421
	US 6977298	B2	20051220
APPLICATION INFO.:	US 2004-4261	A1	20041203 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-264018, filed on 2 Oct 2002, ABANDONED Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2893	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1## As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:315203 USPATFULL
TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
Liu, Jia, La Jolla, CA, UNITED STATES
Matthews, Jean, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248879	A1	20041209
APPLICATION INFO.:	US 2004-811513	A1	20040329 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2003-459433P	20030331 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2003:113513 USPATFULL
 TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
 INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
 Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
 Tikhe, Jayashree, San Diego, CA, UNITED STATES
 Thoresen, Lars Henrik, College Station, TX, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2003078254	A1	20030424
APPLICATION INFO.:	US 2002-264018	A1	20021002 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Agouron Pharmaceuticals, Inc., 10777 Science Center Road, San Diego, CA, 92121	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3013	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1##

As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2002:332731 USPATFULL
 TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
 INVENTOR(S): Webber, Stephen Evan, San Diego, CA, United States
 Canan-Koch, Stacie S., La Jolla, CA, United States

PATENT ASSIGNEE(S): Tikhe, Jayashree, San Diego, CA, United States
Thoresen, Lars Henrik, College Station, TX, United States
Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495541	B1	20021217
APPLICATION INFO.:	US 2000-479896		20000110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Shanks & Herbert	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3029	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. ##STR1##

As **cancer** therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006

L1 1 S 283173-50-2/RN

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006

L2 8 S L1
L3 7 S L2 AND CANCER
L4 1 S L3 AND IRENOTECAN
L5 1 S L3 AND TEMOZOLAMIDE
L6 2 S L3 AND DACARBAZINE
L7 7 DUP REM L3 (0 DUPLICATES REMOVED)
L8 7 S L3-L6
L9 7 DUP REM L8 (0 DUPLICATES REMOVED)